Clinical Trial Update: Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating erlotinib for recurrent or progressive glioblastoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: UNKNOWN